New combo therapy aims to shrink lung tumors before surgery

NCT ID NCT07410975

Recruiting now Disease control Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a mix of two immunotherapy drugs (sintilimab and IBI310) plus chemotherapy before surgery can shrink tumors in people with stage II-III non-small cell lung cancer. About 54 participants will receive the treatment and then have surgery. The main goal is to see how many patients have very few live cancer cells left after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC STAGE II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma type 1 diabetes mellitus 12

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC STAGE II NSCLC, STAGE III

Contacts and locations

Locations

Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.